Simone Rizzetto @SimoneRizzetto88: "📊 PORTFOLIO UPDATE: Guardant Breakthrough..."

Italy

📊 PORTFOLIO UPDATE: Guardant Breakthrough 🚀 One week since the last update and the news flow has been dense. Major news was UnitedHealth's coverage deal sent Guardant soaring, Moderna's Science Day reinforced biotech momentum. Portfolio holding strong. YTD +13.87%, MTD +1.40%. 📌 Biotech ➤ $GH (Guardant Health Inc): UnitedHealth will cover Guardant's Shield CRC screening test starting August 1, expanding access to ~10 million lives. Stock jumped ~14%. Wall Street piled on: Bernstein PT to $200, BTIG to $190, BofA to $190 from $135. Trading near 52-week high of $172.61. ➤ $NTRA (Natera Inc): Multiple upgrades this period. Bernstein resumed Outperform at $310 PT, the highest on Wall Street. Guggenheim raised PT to $290. Signatera received Japan PMDA approval for colorectal cancer and earned NCCN recognition for bladder cancer. Stock hit a record high. ➤ $INCY (Incyte Corp.): EMA's CHMP delivered positive opinion for Opzelura in atopic dermatitis. CMS Medicaid rebate settlement resolved, securing ~$246M benefit. Stock hit 52-week high of $118.69. 📌 Pharma ➤ $MRK (Merck & Co.): FDA approved Keytruda-Trodelvy for triple-negative breast cancer and EC approved Keytruda-Padcev for bladder cancer in the EU. Scotiabank raised PT to $155, BofA to $141. Stock surged 3.3% to $129.85. My position up over 56%. ➤ $BMY (Bristol-Myers Squibb Co): Deep value at 9.1x forward P/E versus sector 24.8x. DCF fair value at $74 implies ~27% upside from $58. Mavacamten expanded with Japan study, 4.34% dividend yield. ➤ $PFE (Pfizer): CEO highlighted "very big balance sheet" for M&A. Jefferies Buy at $34, 40% upside. Ten Phase 3 obesity studies advancing. At 8x forward P/E with 7.07% yield, risk-reward remains compelling. ➤ $GSK.L (GlaxoSmithKline): HSBC upgraded from Reduce to Hold on July 6, PT to £18.60. $10.6B Nuvalent tender expires July 14. Stock crossed above 50-day MA on a 4.6% gain. Q2 earnings July 28. 📌 Insurance ➤ $UNH (UnitedHealth): Morgan Stanley upgraded to Overweight at $468. $3B in AI investment through 2027 already delivering $2 return per dollar invested. Q1 medical care ratio improved to 83.9%. Q2 earnings July 16, consensus EPS $4.84. 19 of 26 analysts rate Strong Buy. 🚀 Semis: Divergence in the AI Trade ➤ $AMD (Advanced Micro Devices Inc): Wells Fargo raised PT to $615 on AI CPU dominance. CPU TAM projected to grow from $29B to $131B by 2030. Advancing AI Summit July 22-23 expected to feature new customer wins. Up 171% YTD but valuation stretched at 54x trailing P/E. I significantly cut AMD recently. ➤ $NVDA (NVIDIA Corporation): Goldman Sachs says the stock is undervalued, arguing current price reflects worst-case scenarios. Pulled back ~17% from highs but analysts note this is a healthy correction pattern. $300 target by late 2027. ➤ $TSM (Taiwan Semiconductor Manufacturing Co Ltd - ADR): BofA raised PT to $590. CoWoS capacity forecast upgraded to 140K units/month. May revenue up 30.1% YoY. Forward P/E of ~26x is a discount to broader semis. Earnings July 16. ➤ $LRCX (Lam Research Corp): Equipment side took a hit. Stock dropped 10.2% on July 2 to $351, reversing part of the 154% H1 gain. Vltava Fund sold position citing overvaluation. Earnings July 29 critical. 📌 Upcoming events Earnings season ahead is packed starting from mid July. $SPX500 $NSDQ100

Not investment advice. The author may have financial interests in the mentioned instruments.